167 related articles for article (PubMed ID: 37847502)
1. Patient and Context Factors in the Adoption of Active Surveillance for Low-Risk Prostate Cancer.
Ciccone G; De Luca S; Oderda M; Munoz F; Krengli M; Allis S; Baima CG; Barale M; Bartoncini S; Beldì D; Bellei L; Bellissimo AR; Bernardi D; Biamino G; Billia M; Borsa R; Cante D; Castelli E; Cattaneo G; Centrella D; Collura D; Coppola P; Dalmasso E; Di Stasio A; Fasolis G; Fiorio M; Garibaldi E; Girelli G; Griffa D; Guercio S; Migliari R; Molinaro L; Montefiore F; Montefusco G; Moroni M; Muto G; Ponti di Sant'Angelo F; Ruggiero L; Ruo Redda MG; Serao A; Squeo MS; Stancati S; Surleti D; Varvello F; Volpe A; Zaramella S; Zarrelli G; Zitella A; Bollito E; Gontero P; Porpiglia F; Galassi C; Bertetto O;
JAMA Netw Open; 2023 Oct; 6(10):e2338039. PubMed ID: 37847502
[TBL] [Abstract][Full Text] [Related]
2. Population-Based Assessment of Determining Treatments for Prostate Cancer.
Chamie K; Williams SB; Hu JC
JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
[TBL] [Abstract][Full Text] [Related]
3. Time Trends and Variation in the Use of Active Surveillance for Management of Low-risk Prostate Cancer in the US.
Cooperberg MR; Meeks W; Fang R; Gaylis FD; Catalona WJ; Makarov DV
JAMA Netw Open; 2023 Mar; 6(3):e231439. PubMed ID: 36862409
[TBL] [Abstract][Full Text] [Related]
4. Association of Prostate-Specific Antigen Velocity With Clinical Progression Among African American and Non-Hispanic White Men Treated for Low-Risk Prostate Cancer With Active Surveillance.
Nelson TJ; Javier-DesLoges J; Deka R; Courtney PT; Nalawade V; Mell L; Murphy J; Parsons JK; Rose BS
JAMA Netw Open; 2021 May; 4(5):e219452. PubMed ID: 33999164
[TBL] [Abstract][Full Text] [Related]
5. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
[TBL] [Abstract][Full Text] [Related]
6. National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
Aghazadeh MA; Frankel J; Belanger M; McLaughlin T; Tortora J; Staff I; Wagner JR
J Urol; 2018 May; 199(5):1196-1201. PubMed ID: 29288120
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life in active surveillance and radical prostatectomy for low-risk prostate cancer: a prospective observational study (HAROW - Hormonal therapy, Active Surveillance, Radiation, Operation, Watchful Waiting).
Ansmann L; Winter N; Ernstmann N; Heidenreich A; Weissbach L; Herden J
BJU Int; 2018 Sep; 122(3):401-410. PubMed ID: 29603553
[TBL] [Abstract][Full Text] [Related]
8. Prevalence, Predictors, and Implications for Appropriate Use of Active Surveillance Management Among Black Men Diagnosed With Low-risk Prostate Cancer.
Taku N; Narayan V; Wang X; Vapiwala N
Am J Clin Oncol; 2019 Jun; 42(6):507-511. PubMed ID: 31045876
[TBL] [Abstract][Full Text] [Related]
9. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer.
Aizer AA; Paly JJ; Zietman AL; Nguyen PL; Beard CJ; Rao SK; Kaplan ID; Niemierko A; Hirsch MS; Wu CL; Olumi AF; Michaelson MD; D'Amico AV; Efstathiou JA
J Clin Oncol; 2012 Sep; 30(25):3071-6. PubMed ID: 22851571
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
Gearman DJ; Morlacco A; Cheville JC; Rangel LJ; Karnes RJ
J Urol; 2018 May; 199(5):1188-1195. PubMed ID: 29225057
[TBL] [Abstract][Full Text] [Related]
11. Tumor Volume on Biopsy of Low Risk Prostate Cancer Managed with Active Surveillance.
Tosoian JJ; Mamawala M; Patel HD; Alam R; Epstein JI; Ross AE; Carter HB
J Urol; 2018 Apr; 199(4):954-960. PubMed ID: 29074222
[TBL] [Abstract][Full Text] [Related]
12. Sexual function with localized prostate cancer: active surveillance vs radical therapy.
van den Bergh RC; Korfage IJ; Roobol MJ; Bangma CH; de Koning HJ; Steyerberg EW; Essink-Bot ML
BJU Int; 2012 Oct; 110(7):1032-9. PubMed ID: 22260273
[TBL] [Abstract][Full Text] [Related]
13. Management Strategies and Patient Selection After a Hospital Funding Reform for Prostate Cancer Surgery in Canada.
Wettstein MS; Palmer KS; Kulkarni GS; Paterson JM; Ling V; Lapointe-Shaw L; Li AH; Brown A; Taljaard M; Ivers N
JAMA Netw Open; 2019 Aug; 2(8):e1910505. PubMed ID: 31469400
[TBL] [Abstract][Full Text] [Related]
14. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
[TBL] [Abstract][Full Text] [Related]
15. Active treatment in low-risk prostate cancer: a population-based study.
Roy S; Hyndman ME; Danielson B; Fairey A; Lee-Ying R; Cheung WY; Afzal AR; Xu Y; Abedin T; Quon HC
Curr Oncol; 2019 Aug; 26(4):e535-e540. PubMed ID: 31548822
[TBL] [Abstract][Full Text] [Related]
16. An evidence review of active surveillance in men with localized prostate cancer.
Ip S; Dahabreh IJ; Chung M; Yu WW; Balk EM; Iovin RC; Mathew P; Luongo T; Dvorak T; Lau J
Evid Rep Technol Assess (Full Rep); 2011 Dec; (204):1-341. PubMed ID: 23126653
[TBL] [Abstract][Full Text] [Related]
17. The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-Stage Prostate Cancer.
Chappidi MR; Bell A; Cowan JE; Greenberg SA; Lonergan PE; Washington SL; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
J Urol; 2022 May; 207(5):1001-1009. PubMed ID: 34981949
[TBL] [Abstract][Full Text] [Related]
18. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.
Fossati N; Karnes RJ; Boorjian SA; Moschini M; Morlacco A; Bossi A; Seisen T; Cozzarini C; Fiorino C; Noris Chiorda B; Gandaglia G; Dell'Oglio P; Joniau S; Tosco L; Shariat S; Goldner G; Hinkelbein W; Bartkowiak D; Haustermans K; Tombal B; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2017 Jun; 71(6):886-893. PubMed ID: 27484843
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance.
Balakrishnan AS; Cowan JE; Cooperberg MR; Shinohara K; Nguyen HG; Carroll PR
J Urol; 2019 Sep; 202(3):506-510. PubMed ID: 30958738
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
